Vir Biotechnology, Inc. VIR was a big mover last session, as the company saw its shares rise nearly 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $16.26 –$60.20 in the past one-month time frame, witnessed a sharp increase yesterday.
The upmove came after the company announced a research collaboration agreement with the National Institutes of Health Vaccine Research Center to develop antibodies against coronaviruses, including SARS-CoV-2.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Vir currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Vir Biotechnology, Inc. Price
Vir Biotechnology, Inc. price | Vir Biotechnology, Inc. Quote
Investors interested in the Medical - Biomedical and Genetics industry may consider Regeneron Pharmaceuticals, Inc. REGN, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is VIR going up? Or down? Predict to see what others think:Up or Down
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
Vir Biotechnology, Inc. (VIR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research